Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Robert D. Suh, MD
Lea Azour, MD
Ashwin Basavaraj, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
New Strategies for Individualizing Treatment in DME
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Marilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Vera Bril, MD
Hans Katzberg, MD
Ocular to Generalized MG: How and Why the Disease Evolves
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Nicholas J. Silvestri, MD
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
What’s New in Suprachoroidal MIGS?
I. Paul Singh, MD
Paul Petrakos, DO, MS
Evolving Strategies for Sustained-Release Glaucoma Treatments
Sarah H. Van Tassel, MD
Justin Schweitzer, OD, FAAO
What’s New in Glaucoma Topical Therapies?
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.